NYSE:ZTS - New York Stock Exchange, Inc. - US98978V1035 - Common Stock - Currency: USD
ZTS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. While ZTS has a great profitability rating, there are some minor concerns on its financial health. ZTS has a decent growth rate and is not valued too expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.86% | ||
ROE | 54.09% | ||
ROIC | 25.63% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 37.11% | ||
PM (TTM) | 27.12% | ||
GM | 70.98% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.12 | ||
Debt/FCF | 2.88 | ||
Altman-Z | 7.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.74 | ||
Quick Ratio | 1.04 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 25.27 | ||
Fwd PE | 22.06 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 29.69 | ||
EV/EBITDA | 18.52 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 1.3% |
152.12
-0.7 (-0.46%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 1.3% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 25.27 | ||
Fwd PE | 22.06 | ||
P/S | 7.29 | ||
P/FCF | 29.69 | ||
P/OCF | 23 | ||
P/B | 14.55 | ||
P/tB | 79.03 | ||
EV/EBITDA | 18.52 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.86% | ||
ROE | 54.09% | ||
ROCE | 32.17% | ||
ROIC | 25.63% | ||
ROICexc | 30.53% | ||
ROICexgc | 52.86% | ||
OM | 37.11% | ||
PM (TTM) | 27.12% | ||
GM | 70.98% | ||
FCFM | 24.56% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.12 | ||
Debt/FCF | 2.88 | ||
Debt/EBITDA | 1.33 | ||
Cap/Depr | 135.51% | ||
Cap/Sales | 7.15% | ||
Interest Coverage | 12.58 | ||
Cash Conversion | 74.82% | ||
Profit Quality | 90.59% | ||
Current Ratio | 1.74 | ||
Quick Ratio | 1.04 | ||
Altman-Z | 7.23 |